T. Feys MBA, MSc

Highlights from the 2017 annual meeting of the International Society on Thrombosis and Haemostasis (Berlin, 8-13 July 2017)

SUMMARY

From July 8–13, Berlin formed the background for the 2017 annual meeting of the International Society on Thrombosis and Haemostasis. During the congress, thousands of the world’s leading experts on thrombosis, haemostasis and vascular biology came together to present the most recent advances, exchange the latest science and discuss the newest clinical applications designed to improve patient care. In this summary, some of the key studies presented at the meeting will be discussed. For a more complete coverage of the meeting, we happily refer to the congress website: www.isth2017.org.

(BELG J HEMATOL 2017;8(5):203–7)

Highlights in thrombosis and inherited platelet disorders

(BELG J HEMATOL 2017;8(4):166–7)

Highlights in indolent non-hodgkin lymphoma and diffuse large B-cell lymphoma

SUMMARY

As usual, June was a very busy month for lymphoma specialists, with back to back, international meetings. This report will summarize some key data related to non-hodgkin lymphoma, presented during the 2017 International Conference on Malignant Lymphoma (ICML; Lugano June 14–17) and the 2017 annual meeting of the European Hematology Association (EHA; Madrid June 22–25). We would like to acknowledge Prof Ann Janssens (University Hospital Leuven) for her help in selecting the abstracts presented here.

(BELG J HEMATOL 2017;8(4):158–64)

Highlights in chronic myeloid leukemia

SUMMARY

Treatment discontinuation has become a central issue in studies with BCR-ABL tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML). The oral session on clinical trials in CML featured two studies on treatment discontinuation: one assessing initial reduction before complete TKI withdrawal and a second study evaluating the impact of minimal residual disease (MRD) on the outcome of imatinib discontinuation. In addition to this, a study was presented with long-term data on 400mg imatinib as first-line treatment for CML together with a study assessing frontline bosutinib. Finally, a last abstract in this session evaluated the second-generation BCR-ABL TKI dasatinib in children and adolescents with CML.

(BELG J HEMATOL 2017;8(4):151–4)

Novelties in the treatment of classical Hodgkin lymphoma

SUMMARY

Practice changing novelties in the treatment of classical Hodgkin lymphoma (cHL) were scarce at EHA 2017. This summary will discuss three abstracts presented during an oral session dedicated to clinical findings in Hodgkin (HL) and indolent Non-Hodgkin Lymphoma (iNHL).

(BELG J HEMATOL 2017;8(4):141–3)

New haematology reimbursements in Belgium

OVERVIEW OF BELGIAN REIMBURSEMENT NEWS

(BELG J HEMATOL 2017;8(3):125–6)

Biosimilars in the Belgian health care plan

(BELG J HEMATOL 2017;8(2):87–8)